Akebia Therapeutics, Inc.

AKBA

US00972D1054

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
0.9465 ^USD	-1.41%		+2.36%	-23.67%

Jul. 01	Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 2500 Index	CI
Jul. 01	Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000 Index	CI

Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000 Index

July 30, 2024

Latest news about Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 2500 Index	Jun. 30	CI
Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000 Index	Jun. 30	CI
Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000E Value Index	Jun. 30	CI
Akebia Therapeutics Names Erik Ostrowski CFO, CBO	Jun. 24	MT
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	Jun. 24	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	Jun. 24	CI
Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M	May. 09	MT
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Averoa Seeks EU Approval for Chronic Kidney Disease Drug	Apr. 23	MT
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	Apr. 16	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	Mar. 28	MT
Sector Update: Health Care	Mar. 28	MT
Transcript : Akebia Therapeutics, Inc. - Special Call	Mar. 28
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	Mar. 28	MT
Akebia Shares Rally Premarket After FDA Approves Vafseo	Mar. 28	DJ
U.S. FDA approves Akebia's anemia drug	Mar. 27	RE
U.S. FDA approves Akebia's anemia drug	Mar. 27	RE
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	Mar. 27	CI
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024	Mar. 15	CI
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024	Mar. 15	CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M	Mar. 14	MT
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Mar. 14	CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI

Chart Akebia Therapeutics, Inc.

Duration

Period

More charts

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Companyâs portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Sector

Biotechnology & Medical Research

Calendar

2024-07-15 - H.C. Wainwright Kidney Virtual Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Akebia Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.96 USD

Average target price

5 USD

Spread / Average Target

+420.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AKEBIA THERAPEUTICS, INC.	-23.67%	201M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs